AtriCure, Inc. $ATRC Stock Position Lessened by Amundi

Key Points

• Amundi has reduced its stake in AtriCure, Inc. (NASDAQ:ATRC) by 5.7%, owning 254,934 shares worth approximately $8.39 million after selling 15,521 shares in Q1.
• AtriCure's recent earnings report revealed a beat in EPS, reporting ($0.02) against a consensus of ($0.15), with revenues up 17.1% year-over-year at $136.14 million.
• Analysts maintain a generally positive outlook for AtriCure, with multiple upgrades and an average target price set at $50.89, reflecting strong confidence in the stock's performance.

Amundi trimmed its holdings in AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 5.7% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 254,934 shares of the medical device company's stock after selling 15,521 shares during the period. Amundi owned about 0.51% of AtriCure worth $8,392,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Northern Trust Corp raised its position in shares of AtriCure by 11.6% during the 4th quarter. Northern Trust Corp now owns 483,607 shares of the medical device company's stock valued at $14,779,000 after acquiring an additional 50,153 shares in the last quarter. Ameriprise Financial Inc. acquired a new stake in shares of AtriCure during the 4th quarter valued at approximately $295,000. BNP Paribas Financial Markets raised its position in shares of AtriCure by 676.4% during the 4th quarter. BNP Paribas Financial Markets now owns 97,310 shares of the medical device company's stock valued at $2,974,000 after acquiring an additional 84,776 shares in the last quarter. Focus Partners Wealth acquired a new stake in shares of AtriCure during the 4th quarter valued at approximately $498,000. Finally, Graham Capital Management L.P. acquired a new stake in shares of AtriCure during the 4th quarter valued at approximately $649,000. 99.11% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at AtriCure

In other news, Director Regina E. Groves sold 2,452 shares of the stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $36.82, for a total value of $90,282.64. Following the completion of the transaction, the director owned 33,715 shares of the company's stock, valued at approximately $1,241,386.30. This represents a 6.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Sven Wehrwein sold 5,000 shares of the stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $37.00, for a total value of $185,000.00. Following the completion of the transaction, the director directly owned 34,374 shares of the company's stock, valued at approximately $1,271,838. The trade was a 12.70% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 14,952 shares of company stock valued at $546,733. 3.50% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on ATRC shares. BTIG Research set a $54.00 price target on AtriCure in a research report on Wednesday, July 30th. Wall Street Zen raised AtriCure from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Finally, Needham & Company LLC upped their price target on AtriCure from $44.00 to $45.00 and gave the company a "buy" rating in a research report on Wednesday, July 30th. Nine investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $50.89.

AtriCure Stock Performance

ATRC traded down $0.44 during trading on Monday, reaching $34.63. 621,571 shares of the company were exchanged, compared to its average volume of 395,097. The stock has a market cap of $1.72 billion, a P/E ratio of -44.97 and a beta of 1.62. The firm has a 50 day moving average of $34.41 and a 200 day moving average of $33.42. The company has a current ratio of 3.94, a quick ratio of 2.83 and a debt-to-equity ratio of 0.16. AtriCure, Inc. has a 52 week low of $25.57 and a 52 week high of $43.11.

AtriCure (NASDAQ:ATRC - Get Free Report) last issued its quarterly earnings data on Tuesday, July 29th. The medical device company reported ($0.02) EPS for the quarter, topping analysts' consensus estimates of ($0.15) by $0.13. AtriCure had a negative return on equity of 4.20% and a negative net margin of 7.27%.The firm had revenue of $136.14 million during the quarter, compared to the consensus estimate of $130.17 million. During the same period in the prior year, the business earned ($0.17) EPS. The firm's revenue was up 17.1% on a year-over-year basis. AtriCure has set its FY 2025 guidance at -0.390--0.340 EPS. On average, sell-side analysts forecast that AtriCure, Inc. will post -0.6 EPS for the current fiscal year.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.